Oral Ferric Citrate Hydrate Associated With Less Oxidative Stress Than Intravenous Saccharated Ferric Oxide

Mimura, 2015, How the target hemoglobin of renal anemia should be, Nephron, 131, 202, 10.1159/000440849 Babitt, 2012, Mechanisms of anemia in CKD, J Am Soc Nephrol, 23, 1631, 10.1681/ASN.2011111078 Zaritsky, 2009, Hepcidin—a potential novel biomarker for iron status in chronic kidney disease, Clin J Am Soc Nephrol, 4, 1051, 10.2215/CJN.05931108 Rostoker, 2016, Iatrogenic iron overload in dialysis patients at the beginning of the 21st century, Drugs, 76, 741, 10.1007/s40265-016-0569-0 Albaramki, 2012, Parenteral versus oral iron therapy for adults and children with chronic kidney disease, Cochrane Database Syst Rev, 1, CD007857 Shepshelovich, 2016, Intravenous versus oral iron supplementation for the treatment of anemia in CKD: an updated systematic review and meta-analysis, Am J Kidney Dis, 68, 677, 10.1053/j.ajkd.2016.04.018 Litton, 2013, Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials, BMJ, 347, f4822, 10.1136/bmj.f4822 Agarwal, 2004, Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease, Kidney Int, 65, 2279, 10.1111/j.1523-1755.2004.00648.x Yokoyama, 2014, JTT-751 for treatment of patients with hyperphosphatemia on peritoneal dialysis, Nephron Clin Pract, 128, 135, 10.1159/000366482 Yokoyama, 2014, A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis, Nephrol Dial Transplant, 29, 1053, 10.1093/ndt/gft483 Yokoyama, 2014, Long-term safety and efficacy of a novel iron-containing phosphate binder, JTT-751, in patients receiving hemodialysis, J Ren Nutr, 24, 261 Yokoyama, 2014, Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD, Clin J Am Soc Nephrol, 9, 543, 10.2215/CJN.05170513 Yokoyama, 2012, Effect of oral JTT-751 (ferric citrate) on hyperphosphatemia in hemodialysis patients: results of a randomized, double-blind, placebo-controlled trial, Am J Nephrol, 36, 478, 10.1159/000344008 Yokoyama, 2017, Ferritin elevation and improved responsiveness to erythropoiesis-stimulating agents in patients on ferric citrate hydrate, Kidney Int Rep, 2, 359, 10.1016/j.ekir.2016.12.005 Umanath, 2015, Ferric citrate reduces intravenous iron and erythropoiesis-stimulating agent use in ESRD, J Am Soc Nephrol, 26, 2578, 10.1681/ASN.2014080842 Block, 2015, A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3–5, Am J Kidney Dis, 65, 728, 10.1053/j.ajkd.2014.10.014 Zanen, 1996, 'Oversaturation' of transferrin after intravenous ferric gluconate (Ferrlecit(R)) in haemodialysis patients, Nephrol Dial Transplant, 11, 820, 10.1093/oxfordjournals.ndt.a027405 Tovbin, 2002, Induction of protein oxidation by intravenous iron in hemodialysis patients: role of inflammation, Am J Kidney Dis, 40, 1005, 10.1053/ajkd.2002.36334 Bishu, 2006, Acute injury with intravenous iron and concerns regarding long-term safety, Clin J Am Soc Nephrol, 1, S19, 10.2215/CJN.01420406 Kuo, 2008, Intravenous iron exacerbates oxidative DNA damage in peripheral blood lymphocytes in chronic hemodialysis patients, J Am Soc Nephrol, 19, 1817, 10.1681/ASN.2007101084 Garcia-Fernandez, 2010, Randomized clinical trial on acute effects of i.v. iron sucrose during haemodialysis, Nephrology (Carlton), 15, 178, 10.1111/j.1440-1797.2009.01174.x Shema-Didi, 2013, Pomegranate juice intake attenuates the increase in oxidative stress induced by intravenous iron during hemodialysis, Nutr Res, 33, 442, 10.1016/j.nutres.2013.04.004 Showkat, 2014, Effect of alpha-lipoic acid on oxidative stress in end-stage renal disease patients receiving intravenous iron, ISRN Nephrol, 2014, 634515, 10.1155/2014/634515 Gupta, 2016, Ferrous iron content of intravenous iron formulations, Biometals, 29, 411, 10.1007/s10534-016-9923-7 Kalantar-Zadeh, 2006, Serum myeloperoxidase and mortality in maintenance hemodialysis patients, Am J Kidney Dis, 48, 59, 10.1053/j.ajkd.2006.03.047 Wang, 2010, Prognostic value of plasma myeloperoxidase in ESRD patients, Am J Kidney Dis, 56, 937, 10.1053/j.ajkd.2010.05.008 Kuo, 2012, Intravenous ferric chloride hexahydrate supplementation induced endothelial dysfunction and increased cardiovascular risk among hemodialysis patients, PLoS One, 7, e50295, 10.1371/journal.pone.0050295 Bailie, 2015, Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality, Kidney Int, 87, 162, 10.1038/ki.2014.275 Wolf, 2013, Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women, J Bone Miner Res, 28, 1793, 10.1002/jbmr.1923 Takeda, 2011, Effect of intravenous saccharated ferric oxide on serum FGF23 and mineral metabolism in hemodialysis patients, Am J Nephrol, 33, 421, 10.1159/000327019